Clinical Trial · NCT05013086

177Lu-AB-3PRGD2 in Patients With Integrin αVβ3 Positive Tumors

Overview

This is an open-label, non-controlled, non-randomized study to assess the safety and measure image-based absorbed dose of 177Lu-AB-3PRGD2 in patients with Integrin αVβ3 positive tumors who will undergo radioliagnd therapy using 177Lu-AB-3PRGD2.

Sponsor

Peking Union Medical College Hospital

Phase

Early Phase 1

Contacts

Zhaohui Zhu, MD (CONTACT)

13611093752@163.com

86-13611093752

Guochang Wang, MD (CONTACT)

guochang1007@163.com

86-18516822732

Zhaohui Zhu, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT05013086

Eligibility

Inclusion

signed written consent.
patients with clear pathological diagnosis and ineffective or progressing clinical conventional treatment;
tumor lesions with high RGD untake confirmed on 68Ga-RGD PET/CT within one week before the injection of 177Lu-AB-3PRGD2;

Exclusion

the exclusion criteria were a serum creatinine level of more than 150 μmol per liter, a hemoglobin level of less than 10.0 g/dl, a white-cell count of less than 4.0× 109/L, a platelet count of less than 100 × 109/L, a total bilirubin level of more than 3 times the upper limit of the normal range and a serum albumin level of more than 3.0 g per deciliter, cardiac insufficiency including carcinoid heart valve disease, a severe allergy or hypersensitivity to radiographic contrast material, claustrophobia;
any medical condition that in the opinion of the investigator may significantly interfere with study compliance.